Login to Your Account

IDM Initiating Third Phase II Trial Of Uvidem In Melanoma

By James Etheridge

Wednesday, November 16, 2005
PARIS - IDM Pharma Inc. initiated another Phase II trial of its therapeutic vaccine Uvidem, which it is developing in collaboration with Sanofi-Aventis for the treatment of melanoma. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription